Literature DB >> 17688279

Behaviour of polysorbate 20 during dialysis, concentration and filtration using membrane separation techniques.

Hanns-Christian Mahler1, Miriam Printz, Robert Kopf, Rudolf Schuller, Robert Müller.   

Abstract

During formulation development of a therapeutic protein, combinations of buffers, pH and excipients need to be tested. As the protein bulk solution used for formulation development usually contains a buffer component at a defined pH and potentially one or more excipients already, this bulk requires to be processed. In case low concentrations of non-ionic surfactants, for example polysorbate 20, are already present in the bulk, the surfactant needs to be removed in lab-scale for further development use. The scope of the work was to study the behaviour of low concentrations of polysorbate 20 during membrane separation processes. The first part focuses on evaluating the behaviour of polysorbate 20 during a dialysis process, whereas the second part analyses concentration changes of polysorbate during a membrane concentration process using a stirred cell. The third part analyses potential membrane absorption of polysorbate at sterilizing-grade filters. In conclusion, it was found that polysorbate could not be significantly reduced during a dialysis process and accumulated during a membrane concentration process in unreproducable manner. During sterile filtration, no significant influence on the concentration of polysorbate was measurable. In any case, it is recommendable to quantify the concentration of polysorbate during critical membrane process steps in pharmaceutical industry.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17688279     DOI: 10.1002/jps.21029

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.

Authors:  Nidhi Doshi; Jamie Giddings; Lin Luis; Arthur Wu; Kyle Ritchie; Wenqiang Liu; Wayman Chan; Rosalynn Taing; Jeff Chu; Alavattam Sreedhara; Aadithya Kannan; Pervina Kei; Ian Shieh; Tobias Graf; Mark Hu
Journal:  Pharm Res       Date:  2021-03-12       Impact factor: 4.200

Review 2.  In Vivo Stability of Therapeutic Proteins.

Authors:  Joachim Schuster; Atanas Koulov; Hanns-Christian Mahler; Pascal Detampel; Joerg Huwyler; Satish Singh; Roman Mathaes
Journal:  Pharm Res       Date:  2020-01-03       Impact factor: 4.200

3.  Breaking the aggregation of the monoclonal antibody bevacizumab (avastin®) by dexamethasone phosphate: insights from molecular modelling and asymmetrical flow field-flow fractionation.

Authors:  Marieke Veurink; Yvonne Westermaier; Robert Gurny; Leonardo Scapozza
Journal:  Pharm Res       Date:  2013-02-15       Impact factor: 4.200

4.  Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.

Authors:  Nidhi Doshi; Kyle Ritchie; Tamanna Shobha; Jamie Giddings; Kathrin Gregoritza; Rosalynn Taing; Stephen Rumbelow; Jeff Chu; Anthony Tomlinson; Aadithya Kannan; Miguel Saggu; Si Kai Cai; Victor Nicoulin; Wenqiang Liu; Steve Russell; Lin Luis; Sandeep Yadav
Journal:  Pharm Res       Date:  2021-09-08       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.